Summary of VCUs and Orders - 1993

Date of Approval Medicine Patentee %Above Guidelines Price Reduction1 Excess Revenues2 Payments Patent Status
VCUs
Dec. 20, 1993 Lopid/Gemfibrozil (300mg & 600 mg) Parke-Davis 2.5 - 10.8 No $1,635,970 $1,635,970 Dedicated May 4, 1993
Nov. 22, 1993 Megace (40 &
160 mg)		 Bristol-Myers Squibb 7.6 - 12.6 No $993,157 $993,157 Dedicated July 19 ,1993
Nov. 2, 1993 Hytrin (10 mg) Abbott Laboratories Limited 25 Yes - $1.37/tablet $24,510 $24,510
Sept. 28, 1993 Metrogel (7.5
mg/g)		 Cyanamid Canada Inc. Lederle Laboratories 26 Yes - $17.43/tube $406,642 $406,642
June 10, 1993 Imovane (7.5 mg) Rhône Poulenc Rorer Canada Inc. n/a No $1,663,393 $1,663,393 Dedicated July 3, 1992
June 2, 1993 Activase (vials)3 Genentech Canada Inc. n/a No $1,755,000 $1,755,000 Dedicated July 7, 1992
ORDER
  1. There are no price reductions in cases where the PMPRB's jurisdiction ceased with the expiry or the dedication (prior to 1995) of the patent.
  2. In all cases, all excess revenues were offset through further price reduction and/or payment.
  3. Notice of Hearing issued on July 3, 1992.
Date modified: